EUCTR2022-003049-37-BE进行中（未招募）1 期
uteal phase ovarian stimulation with Follitropin delta and dydrogesterone: a randomized cross over pilot trial - Lady De
Z Brussel0 个研究点目标入组 50 人开始时间: 2022年10月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Age from = 18 to = 36 years
- •Body mass Index (BMI) =18 to < 28
- •Signed informed consent
- •Regular menstrual cycle length i.e. 24-35 days
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Contraindications to the use of gonadotropins
- •Endometriosis grade 3-4
- •Patients with Anti-mullerian hormone (AMH) <1.1 ng/ml and/or AFC<7
- •Patients with Follicle Number Per Ovary (FNPO) = 19 and/or AMH >5ng/ml (Fraissinet A et al, 2017)
- •Patients under contraception with hormonal intrauterine device (IUD)
- •Any untreated endocrine abnormality
研究者
相似试验
进行中（未招募）
1 期
uteal phase ovarian stimulation with Follitropin delta and dydrogesteroneVolutary women who wish to donate their oocytesCTIS2024-513998-48-00niversitair Ziekenhuis Brussel50
尚未招募
4 期
se of Follitropin Delta associated with Menotropin to induce ovulation in high-risk patients for Poor Response in In Vitro FertilizatioInfertilityRBR-2kmyfmClinica Vidabemvinda
已完成
不适用
Ovarian stimulation with follicle stimulating hormone (r-FSH) for women with high early follicular FSH and intra-uterine insemination (IUI) indicatioISRCTN14825568VU University Medical Centre (VUMC) (Netherlands)80
进行中（未招募）
1 期
Suppression of Ovarian Funktion Trial (SOFT)Histologically proven, resected breast cancer with ER and/or PgR positive tumorsMedDRA version: 19.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000166-13-DEGBG Forschungs GmbH3,000
进行中（未招募）
1 期
A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. - Suppression of Ovarian Funktion Trial (SOFT)Histologically proven, resected breast cancer with ER and/or PgR positive tumorsMedDRA version: 7.0Level: LLTClassification code 10057654EUCTR2004-000166-13-DKInternational Breast Cancer Study Group (IBCSG)3,000